Studies related to Creatine Kinase and Coenzyme Q10

Coenzyme Q10 Administration Has No Effect On SICAM-1 And Metabolic Parameters Of Pediatrics With Type 1 Diabetes Mellitus

Effect Decrease
Values μkat/L. Mean and SD. Baseline (for all): 2.19 ± 1.32 Control: 2.04 ± 0.79 Omega-3: 2.71 ± 1.98 Omega-3-COQ10: 2.11 ± 1.95
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 105
Sex Both Genders
Notes for this study:
In a randomized, double-blind, controlled trial, 105 participants with dyslipidemia and elevated triglycerides who were taking statins were allocated to take 2.52 g of PUFA or PUFA with 200 mg of coenzyme q10 daily, or no intervention and continued their normal medication for 3 months.

There were no statistically significant differences between the PUFA group and the PUFA + Coenzyme q10 group besides a greater reduction in total cholesterol in the latter group. (Nonsignificant findings can be found in the values boxes of their respective entries).